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Abstract: 
There is strong evidence of a key role for mitochondrial dysfunction in both sporadic and all 
IRUPVRIIDPLOLDO3DUNLQVRQ·VGLVHDVH3'+RZHYHUQRQHRIWKHFOLQLFDOWULDOVFDUULHGRXW
with putative mitochondrial rescue agents has been successful. Firm establishment of a wet 
biomarker or a reliable readout from imaging studies detecting mitochondrial dysfunction 
and reflecting disease progression is also awaited. We will provide an overview of our 
current knowledge about mitochondrial dysfunction in PD and related drug screens. We 
will also summarize previously undertaken mitochondrial wet biomarker studies and 
relevant imaging studies with particular focus on 31P-MRI Spectroscopy. We will conclude 
with an overview of clinical trials which tested putative mitochondrial rescue agents in PD 
patients. 
 
3DUNLQVRQ·VGLVHDVHLVDFRPPRQUHOHQWOHVVO\SURJUHVVLYHQHXURGHJHQHUDWLYHGLVRUGHU7KH
pathological hallmark is loss of dopaminergic neurons in the substantia nigra. The resulting 
motor presentation includes rest tremor, bradykinesia and rigidity but the importance of 
non-motor symptoms such as cognitive impairment and depression is increasingly 
recognized, too. Currently available dopaminergic treatment often only addresses the motor 
impairment partially. This review will summarize our current knowledge about 
mitochondrial dysfunction as a key target for disease-modifying treatment for PD. We will 
also provide an update on mitochondrial readouts in PD patients, namely imaging and 
putative mitochondrial biomarkers, which may become highly relevant in the context of 
future drug trials.  
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Experimental evidence for mitochondrial dysfunction in PD 
The mitochondria are an organelle central to cellular energy production through the 
generation of ATP through oxidative phosphorylation. They are also involved in other 
functions such as; apoptosis, scavenging of free radicals, and calcium homeostasis [1]. 
Mitochondria were first implicated in the pathogenesis of ParkLQVRQ·VGLVHDVH3'ZKHQLW
was discovered that exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
which metabolises to the complex I inhibitor MPP+, induces a Parkinsonian phenotype and 
loss of dopaminergic neurons in the substantia nigra (SN) [2]. 
   
Neurons are particularly susceptible to mitochondrial dysfunction, largely due to their 
extremely high metabolic requirements [3]. Nigral neurons - the cell type predominantly 
affected in PD ² have a higher rate of basal oxidative phosphorylation compared to ventral 
tegmental area neurons, which are unaffected in PD [4]. This may lead to higher levels of 
oxidative stress, due to the production of reactive oxygen species (ROS) by the respiratory 
chain complexes [4]. These neurons also have a higher density of axonal mitochondria which 
may confer a further increase in risk [5].  
 
 
ATP production and oxidative phosphorylation complex dysfunction: Reduced complex I activity 
was first observed in sporadic PD post-mortem brain tissue [6], and platelets [7]. As well as 
in sporadic cases, mitochondrial dysfunction has been implicated in both autosomal 
recessive forms of PD (with mutations in parkin/PARK2, PINK1/PARK6, or DJ-1/PARK7), 
and autosomal dominant forms of PD (with mutations in alpha-synuclein/PARK1/4 and 
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LRRK2/PARK8, see Figure 1) [8]. For example, fibroblasts derived from patients with parkin 
mutations show a distinct complex I deficiency, resulting in reduced ATP levels [9]. Oxygen 
consumption is also reduced in parkin mutant Drosophila larvae [10], parkin knockdown 
zebrafish embryos also have lowered complex I activity [11]. Interestingly, many of the 
genes associated with familial PD are involved in maintaining normal mitochondrial 
function. For example, PINK1 and PARKIN  are important for mitophagy [12], Dj-1 is 
thought to be a redox sensor and can protect cells from oxidative stress [13], and LRRK2 is 
thought to be involved in regulating mitochondrial fission [14].  
 
Autosomal dominantly inherited, heterozygous mutations in LRRK2 are the most common 
cause of familial PD with G2019S being the most frequent mutation [15,16]. In LRRK2G2019S 
mutant fibroblasts, Mortiboys et al. 2015 described a reduction in oxygen consumption. In 
contrast, Papkovskaia et al. 2012 found an increase in oxygen consumption. This may be due 
to the fibroblasts being grown in different media types, galactose containing, and glucose 
containing, respectively [17,18]. It has also been proposed that uncoupling proteins (UCPs) 
could be a biomarker for familial PD, as LRRK2G2019S mutant fibroblasts have increased UCP2 
mRNA expression [18,19]. UCPs allow the passage of hydrogen ions from the 
intermembrane space to the matrix independent from complex V [20]. It is thought that 
UCP2 is protective against mitochondrial ROS levels by reducing the mitochondrial proton 
gradient, this may therefore be a compensatory mechanism against oxidative stress [19]. 
LRRK2G2019S mutant fibroblasts have reduced complex III and IV activity [17,21]. In contrast, 
heterozygous knock-in LRRK2G2019S mice show increases in complex V subunit ATP5A, and 
complex III subunit UQCR2 protein expression, whilst homozygous LRRK2G2019S knock-in 
mice have reduced complex I subunit NDUFB8 expression [22].  
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Interestingly, not only have individual complex dysfunctions been implicated in PD but also 
the supercomplexes that these form. Supercomplexes are thought to increase the efficiency 
of electron carrier transport and the oxidation of multiple substrates, decrease ROS 
production, and are essential in complex I stability [23,24]. The disorganisation of 
mitochondrial supercomplexes has been observed in PINK1 mutant human fibroblasts and 
Pink1 mutant mouse primary neurons, as well as in Dj1 mutant mouse primary neurons and 
brain tissue [25]. A pink mutant zebrafish line also has specific decrease in complex I and III 
activity [26]. Inactivation of the mitochondrial calcium uniporter rescues this complex I 
deficiency in pink1 mutant zebrafish, suggesting that mitochondrial calcium homeostasis is 
crucial for maintaining normal function of the mitochondrial respiratory chain [27]. 
 
Mitochondrial DNA and PD: mtDNA may be more susceptible than nuclear DNA to damage 
due to its higher exposure to ROS generated by oxidative phosphorylation [28]. Selective 
mtDNA damage has been found in nigral, but not cortical neurons, in PD post-mortem brain 
tissue [29]. There is also an increase in mtDNA somatic point mutations, especially in genes 
encoding mitochondrial complex IV [30]. Additionally, there are higher levels of mtDNA 
deletions in PD compared with age matched controls [31], which is associated with 
decreased complex IV activity. mtDNA deletions also occur during normal ageing, however 
the mtDNA copy number increases to compensate for this in healthy controls [32]. This 
upregulation of copy number does not to occur in PD, indicating that mtDNA homeostasis 
is dysregulated [32].  
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Morphology: The regulation of mitochondrial morphology is a tightly controlled process. 
Optic atrophy protein 1 (OPA1), mitofusin 1 (MFN1), and MFN2 are involved in 
mitochondrial fusion, whilst dynamin-related protein (DRP1) regulates mitochondrial 
fission [33]. Mitochondria in post-mortem biopsy samples of the caudate nucleus and 
skeletal muscle of sporadic PD patients are more variable in size and shape [34,35]. 
However, morphology changes are difficult to assess in detail in post-mortem PD brain 
tissue due to the limited preservation of mitochondrial ultrastructural details [8]. 
Interestingly, increased mitochondrial branching has been described in parkin mutant 
human fibroblasts [9]. In addition, morphological abnormalities, such as swollen 
mitochondrial cristae and a decrease in density of normal mitochondria, have been found in 
induced pluripotent stem cell-derived parkin mutant neurons [36].  
 
Changes in mitochondrial morphology have also been observed in various PD animal 
models. For example, an early study looking at mitochondrial abnormalities in Parkin 
mutants, observed that in Parkin null Drosophila, mitochondria are swollen and have 
severely disintegrated cristae [37]. Drosophila primary neurons treated with MPP+ also 
show a reduction in size, number, and an increase in fragmentation prior to cell death [38]. 
LRRK2G2019S knock-in mouse models show altered mitochondrial morphology within the 
striatum including; a beads-on-a-string like appearance, condensation, reduction in number 
through autophagic degradation, and an approximately 10% increase in mitochondria 
length [22,39,40]. Interestingly, LRRK2 phosphorylates DRP1, mediating mitochondrial 
fission. Disruptions to DRP1-mediated fission via LRRK2 mutations could lead to changes in 
mitochondrial dynamics [14,41,42]. 
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Mitophagy: The removal of typically dysfunctional mitochondria, mitophagy, is a highly 
important cellular process, as the accumulation of dysfunctional mitochondria can lead to 
cellular damage. PINK1 and parkin, two genes which have been associated with autosomal 
recessively inherited familial PD, encode proteins which are essential in mitophagy [12]. 
PINK1 acts upstream of Parkin [43,44]. PINK1 phosphorylates both ubiquitin and Parkin at 
its ubiquitin-like domain, to activate parkin as an E3 ligase [45]. This allows the 
ubiquitination of substrates such as DRP1 and Miro [46,47].  
  
Miro is a protein found on the outer membrane of the mitochondria and connects them to 
dynein and kinesin motors, enabling microtubule-based transport [48]. The PINK1/Parkin 
pathway targets Miro for proteasomal degradation prior to mitophagy [47]. Interestingly, 
LRRK2 is also involved in Miro degradation. The disruption of both Parkin and LRRK2 
recruitment to damaged mitochondria coincides with the accumulation of Miro, and leads to 
a delay in mitophagy in fibroblasts from sporadic PD patients [49]. This could be a potential 
pathway where both familial and sporadic PD converge.  
 
As well as impaired clearance of damaged mitochondria, the generation of new 
mitochondria may also be impaired in PD. Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC1-ǂUHJXODWHVPLWRFKRQGULDELRJHQHVLVE\LQGXFLQJWKH
expression of several key biogenesis proteins [50]. PGC1- ǂNQRFNGRZQLQFUHDVHVǂ-
synuclein aggregation in human neuronal cells, and overexpressing PGC1- ǂUHGXFHVWKH
mitochondrial deficiencies seen in MPP+ treated SH-SY5Y cells, such as reduced ATP levels 
[51,52]. The role of mitophagy in PD is a major area of intense investigation and discussing it 
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fully is beyond the scope of this review. Some recent reviews have covered this area in 
greater detail [53²56]. 
 
Transport: It is important that mitochondria can be transported effectively along the 
extended length of neurons and meeting the high energy demands of synapses at the axon 
terminals [57]. LRRK2 mutations in the Roc-COR domain, LRRK2R1441C and LRRK2Y1699C, 
inhibit bidirectional axonal transport of mitochondria in both Drosophila larvae motor 
neurons, and rat cortical neuron cultures. However, this effect is not observed in LRRK2G2019S 
mutant Drosophila [58], suggesting that mutations in the different LRRK2 domains may 
result in distinct phenotypes. These models use ectopically expressed LRRK2 mutations, 
therefore it would be important to also examine mitochondrial transport when these LRRK2 
mutants are expressed at the endogenous locus. This could be achieved using techniques 
such as CRISPR/Cas9.  
To summarize, a wide range of different mitochondrial abnormalities has been reported in 
PD, including lowered ATP production, oxidative phosphorylation and mitochondrial 
respiratory chain complex function, abnormal morphology, disturbed transport and 
impaired mitophagy.  
 
7DUJHWLQJPLWRFKRQGULDIRUQHXURSURWHFWLRQLQ3DUNLQVRQ·VGLVHDVH 
As outlined above a large body of evidence exists for the presence of mitochondrial 
dysfunction in most forms of PD; however there are a limited number of actual 
drug/compound screens which have been reported investigating mitochondrial protective 
compounds. A robust, reproducible and biologically meaningful assay is required which is 
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amenable to high through put screening. These screens could be target based or phenotypic 
in nature; however the same strict criteria of assay robustness and signal to noise window 
must be adhered to.  
 
Instead of large compound screens, much research has been undertaken investigating 
mitochondrial protective compounds on a smaller scale. Cybrid cells generated by using 
mitochondria from sporadic PD patients fused with a parental osteosarcoma cell line create 
cells with a control nuclear background and the mitochondria from sporadic PD patients 
with altered mitochondrial cellular distribution and reduced mitochondrial membrane 
potential [59]. These abnormalities, in addition to autophagy/lysosome abnormalities were 
restored after treatment with NAP (davunetide), an eight amino acid peptide which 
associates with tubulin and enhances correct microtubule assembly. Other work 
investigating mitochondrial abnormalities in PD patient cells has shown a protective effect 
of resveratrol. Resveratrol is a natural polyphenolic compound which activates PGC1-alpha, 
a master regulator of mitochondrial biogenesis. parkin mutant patient fibroblasts showed 
reduced oxygen consumption, complex I deficiencies and pAMPK/AMPK ratio levels which 
all improved upon treatment with resveratrol [60]. In addition this study showed there had 
been a switch to glycolysis that in untreated parkin mutant fibroblasts, resveratrol treatment 
caused a switch back to oxidative phosphorylation [60]. Human pluripotent stem cell 
derived dopaminergic neurons with MPTP or rotenone induced toxicity have been used for 
small scale screens [61]. Dopaminergic neurons were differentiated from stem cells and 
mitochondrial dysfunction induced using either MPTP or rotenone treatment; this enabled 
not only mitochondrial phenotypes to be assessed but also the number of dopaminergic 
neurons surviving after compound treatment. The primary screen assessed the effect of 44 
compounds with three compounds subsequently chosen for further validation with known 
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mechanism of actions including an antioxidant, an anti-inflammatory drug and an mono-
aminooxidase A inhibitor. The protective effect of these compounds was validated in the 
rotenone induced toxicity dopaminergic neuron model [61]. Interestingly this study also 
identified again resveratrol as a positive hit compound. 
 
A limited number of larger compound screens have been undertaken and are detailed 
below. We have previously undertaken the first drug screen in PD patient tissue using 
fibroblasts from parkin mutant patients [62]. In this study we used mitochondrial membrane 
potential as the screening assay; a parameter which we had previously identified as being 
reduced in these parkin mutant fibroblasts [9]. We screened 2000 compounds for their rescue 
effect on mitochondrial membrane potential in fibroblasts from two parkin mutant patients. 
We furthermore undertook secondary screening utilising cellular ATP levels (also reduced 
in untreated parkin mutant fibroblasts versus controls) over a range of concentrations. We 
subsequently undertook measurement of the individual respiratory chain complexes with 
WKH¶WRSKLW·FRmpound (ursocholanic acid, UCA). 24 hour treatment with UCA increased the 
activity of complexes I, II, III and IV in both control and parkin mutant fibroblasts. Based 
upon the structure of UCA we identified another compound which was not included in the 
original screening library, ursodeoxycholic acid (UDCA) which is already licensed for use in 
man for the treatment of primary biliary cirrhosis. We subsequently observed a 
mitochondrial rescue effect of UDCA in parkin mutant fibroblasts as well as LRRK2G2019S 
mutant fibroblasts from manifesting and non-manifesting carriers [17,62]. The beneficial 
effect of UDCA was confirmed in parkin deficient mouse primary cortical neurons and a 
LRRK2G2019S transgenic Drosophila model [57].  
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UDCA also has a protective effect in several other models of PD. Treatment with UDCA 
attenuates the toxic effects of sodium nitroprusside in a SHSY5Y model of PD. SHSY5Y are a 
human, neuroblastoma derived cell line. Specifically, the levels of reactive oxygen species 
were normalised, mitochondrial membrane potential was maintained and cellular 
glutathione levels restored [63]. Furthermore several markers of apoptosis were attenuated 
including caspase 3 activation and nuclear fragmentation. Other, subsequent studies using 
TUDCA, the taurine conjugate of UDCA have shown very similar effects in the SHSY5Y 
model after CCCP treatment [64]; mitochondrial membrane potential and reactive oxygen 
species were again normalised after TUDCA treatment. Mitochondrial dysfunction has been 
noted as a major phenotype in several C. elegans genetic models of PD induced by expressing 
or deleting alpha synuclein, parkin or DJ1 [65]. Treating these mutant c.elegans strains with 
TUDCA gave full protection against further toxic insult. TUDCA also recovers a 
mitochondrial and endoplasmic reticulum (ER) phenotype observed in Drosphila models; 
ablation of Marf1 (a mitochondrial assembly regulatory factor) in Drosophila induces a 
combined phenotype of mitochondrial and ER stress which is ameliorated by treatment with 
TUDCA [66].  In a rotenone induced rat model of PD UDCA treatment normalised ATP 
levels, increased dopamine content, reduced (and therefore returned to normal) expression 
of NFkb, Bcl-2, Bax and caspase 9, reduced caspase 8, 3 and 9 activation and dampened the 
inflammatory response of TNFa and interleukins [67]. UDCA also improved mitochondrial 
morphology by EM and increased striatal dopamine (DA) levels 3 fold. TUDCA treatment 
was also effective in protecting against MPTP induced Parkinsonism in rodents; this effect 
was mediated by reducing reactive oxygen species and activating Akt with subsequent 
activation of Akt-mediated, downstream pro-survival pathways [68]. 
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Other in vitro compound screens to date have utilised alpha-synculein over-expression 
induced toxicity identifying AGK2, a Sirt-2 inhibitor, as a potential candidate compound 
[69]. A compound screen utilising rotenone induced toxicity in SHSY5Y cells identified 
carnosic acid as a suppressor of toxicity [70]. Yeast systems have been utilised by several 
groups to perform compound screens investigating mitochondrial protection. Su et al 
undertook a screen of 115,000 compounds in yeast with validation of the top hits in an alpha 
synuclein-transgenic C. elegans model with downregulated transcriptional profile of 
mitochondrial genes, abnormal mitochondrial morphology and increased ROS production. 
Initial compounds were selected based upon their ability to restore growth and prevent cell 
death; subsequently these compounds were found to partially reverse the mitochondrial 
transcriptional changes as well as functionally restoring mitochondrial morphology and 
reducing ROS production [71]. Taken together, our studies and the work of others have 
identified a number of promising mitochondrial protective compounds, some of which 
warrant further investigation for their efficacy in clinical trials. 
 
Mitochondrial dysfunction and the search for PaUNLQVRQ·VGLVHDVHELRPDUNHUV 
The development of robust biomarkers in PD has long been a priority for clinicians and 
researchers alike. Biomarkers that are sensitive, specific and predictive of disease course, or 
able to monitor response to treatment would drastically change clinical practice. PD remains 
a clinical diagnosis in practice, but a biomarker exhibiting these qualities would potentially 
allow earlier detection of the disease, differentiation between PD and other extrapyramidal 
disorders such as multisystem atrophy (MSA) or even the diagnosis of PD in prodromal 
phases. For example, the association between REM sleep behaviour disorder (RBD) and PD 
is well developed now, and a biomarker able to determine those with RBD who will 
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progress to PD would be a huge step forward in preventing progression of the disease once 
effective disease modifying therapies are available. Even without disease modifying 
therapies, the development of biomarkers to aid in diagnosis and prognosis would be of 
benefit to cliniciDQDQGSDWLHQW+DYLQJREMHFWLYHHYLGHQFHRIDSDWLHQW·VGLVHDVHVWDWHPD\
allow clinicians to deliver a more accurate prognosis in terms of cognitive involvement, 
motor symptoms or potential response to specific therapies. Furthermore, having 
biomarkers that could monitor response to therapy would give objective guidance in 
tailoring and optimising the management of individual PD patients. 
  
As described above, mitochondrial dysfunction and oxidative stress are intrinsically related, 
key players in the pathogenesis of PD and a common pathological step in seemingly all 
forms of idiopoathic and familial PD, regardless of the many genetic factors involved. Thus, 
searching for biomarkers based upon this critical pathological process seems an ideal 
approach. Here we will discuss the previously researched biomarkers and those that are 
becoming increasingly more relevant. 
 
8-hydroxyguanosine and 8-hydroxy-2-deoxyguanosine: 8-hydroxyguanosine (8-OHG) and 8-
hydroxy-2-deoxyguanosine (8-OHdG) are produced when reactive oxygen species (ROS) 
hydroxylate the C-8 position of deoxyguanosine or guanosine residues in DNA and RNA. 
Post mortem midbrain sections of the substantia nigra (SN) in 6 PD patients show clear 
evidence of cytoplasmic nucleic acid damage with significantly elevated levels of 8-OHG in 
patients compared to 8 controls, but also compared to 4 Dementia with Lewy bodies (DLB) 
cases and 4 multiple system atrophy with parkinsonian symptoms cases (MSA-P) [72]. 
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Although less invasive tests are generally preferable both serum and urinary 8-OHG/8-
OHdG will still be confounded by other systemic processes. CSF analysis may therefore 
allow the quantification of 8-OHG in relation to CNS oxidative stress more accurately CSF 8-
OHG was significantly raised in 24 PD patients with a negative correlation with disease 
duration, and no clear correlation with serum levels [73]. These results were replicated in a 
study of 101 PD patients using ELISA to examine 8-OHG in the CSF [74]. A study of 20 
patients found significantly greater levels of 8-OHG in PD patients using HPLC and 
correlated with disease duration  [75]. However, although 8-OHG does seem clearly 
elevated in the CSF of PD patients, similar changes were also observed in the CSF of MSA 
patients (with no significant difference between MSA and PD) and AO]KHLPHU·VGLVHDVH
[76,77]. Thus, 8-OHG appears to be a nonspecific marker, reflecting cell stress/DNA damage 
across different neurodegenerative disorders.  
 
Assessment of serum levels of 8-OHG in a small study of 24 untreated PD patients found no 
difference between PD compared to controls using gradient reversed-phase HPLC [73]. 
However, a slightly larger study of 48 PD patients and 22 age matched controls did find a 
significant difference in total serum levels between these groups using an ELISA method. 
There was no correlation between serum levels and age, age of onset or disease duration and 
no significant differences when comparing groups by PD medication use. Of note, the 8-
OHG levels were higher in the serum of female PD patients compared to male [76]. A larger 
study of 211 PD patients examining leucocyte derived 8-OHG (thus trying to directly 
measure intracellular 8-OHG) using HPLC again detected higher levels when comparing PD 
to control subjects and this difference increased with disease severity independent of 
levodopa treatment [78]. This larger study also seemed to better control for confounding 
factors (such as smoking and diabetes).   
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Urinary 8-OHdG was also elevated in 61 PD patients compared to age-matched controls 
using gas chromatography-mass spectroscopy. Interestingly 8-OHdG was higher in the early 
stages of the disease before trending down, and there was a significant negative correlation 
between cumulative levodopa intake (which would increase with length of disease) and 
urinary 8-OHdG [79]. However this trend of reduction in 8-OHdG with disease duration has 
not been replicated in another similarly sized study of 72 patients using ELISA technique 
which found a positive correlation with disease duration [80] . Urinary 8-OHdG can also be 
elevated in other disease states including malignancy, somewhat hampering the specificity 
of this method [81]. 
 
In conclusion, although it seems well documented that 8-OHG is elevated in CSF (and 
serum in some studies) of PD patients it seems to lack specificity and poorly correlates to 
desirable clinical measures. Of note, many of these studies were small with poor correction 
for confounding factors and ELISA seemed to detect much larger quantities of 8-OHG/8-
OHdG compared to HPLC making comparison difficult. 
 
Glutathione and Glutathione-S-transferase: Glutathione is a reducing agent that acts through 
the catalytic action of glutathione-S-transferase to reduce xenobiotics and electrophiles 
under oxidative stress. Oxidised glutathione has been measured in CSF as well with one 
post mortem study of 48 CSF samples finding significantly reduced levels of CSF oxidised 
glutathione compared to controls [82], however total glutathione levels in the CSF do not 
VHHPWRGLIIHUEHWZHHQ3'06$$O]KHLPHU·Vand age matched controls [83]. Oxidised 
glutathione was significantly higher in 80 PD patients compared to controls but there was no 
difference in total or reduced glutathione [84]. Serum glutathione peroxidase (an antioxidant 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
enzyme utilising glutathione) had a higher activity in 29 PD patients compared to controls 
but this result awaits confirmation in a larger study [85]. Glutathione-S-transferase (GST), 
especially its Pi (GST-Pi) isoform was markedly increased in post mortem frontal cortex 
samples of PD patients [86]. In contrast, GST-Pi was decreased in the CSF of 43 PD patients 
[87]. To summarize, there is a paucity of studies examining consistently different measures 
of glutathione including total glutathione, oxidised glutathione GST-Pi, and glutathione 
peroxidase. This makes comparison and synthesis of this data difficult.  
 
DJ-1: DJ-1 is the protein encoded by the gene DJ-1 at the PARK7 locus with a still relatively 
unclear action. It appears to have a key role in oxidative stress where it stabilises Nrf2, a 
transcription regulator for antioxidant responses [88]. It also undergoes C-terminal cleavage 
in mild oxidative stress allowing it to exhibit a protease function that seems cytoprotective 
against oxidative stress induced apoptosis [89]. Under oxidative stress it also seems 
neuroprotective upon localizing to mitochondrial membranes and the cell nucleus [90]. 
Although contentious in its inclusion in this section, DJ-1 seems intimately related to 
mitochondrial dysfunction and oxidative stress. CSF analysis of DJ-1 has bought about 
varied results. Total DJ-1 in CSF by immunoblot assay showed a significant upregulation of 
DJ-1 in 40 PD patients in early stages of the disease compared to both later stages and 
control groups. However, there was no difference between the late stages of the disease and 
controls [91]. DJ-1 in CSF analysis using ELISA showed elevated levels in both MSA and PD 
patients (n=18 and 36 respectively) compared to controls. There was also a difference 
between MSA and PD, with a mean of 710ng/L in MSA compared to 525ng/L in PD with 
418ng/L in controls [92]. Another group used a Luminex assay and mass spectrometry to 
quantify DJ-1 in CSF of 117 PD and 50 AD cases as well as controls. A lower level of total DJ-
1 in CSF was observed in PD compared to both healthy controls and AD once haemoglobin 
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contamination had been removed as a confounder. There was no difference between AD and 
controls [93]. Studies looking at total DJ-1 in serum and plasma were contradictory with the 
initial study finding an increase in total DJ-1 in 104 PD patients compared to controls [94]. 
However, a subsequent study did not find any differences between 95 PD cases and 
controls, both these studies used a similar ELISA techniques [95].  To try and clarify these 
results a further study used a Luminex assay and separated out all cell components from 
plasma and controlled for confounders such as platelet contamination and haemolysis given 
that 95% of DJ-1 in the blood is located in red blood cells. This very thorough approach did 
not reveal any differences of plasma DJ-1 levels between 126 PD patients, 33 AD patients 
and 122 controls [96]. Since then DJ-1 has been analysed further in the serum, looking closely 
at DJ-1 protein and the isoforms generated in post translational modification showed a 
specific isoform that was significantly decreased in 75 PD patients and 14 AD patients 
compared to 30 controls and one isoform that was increased in PD and AD, however both of 
these isoforms lacked specificity for either condition. Additionally assessing for specific 
post-translational modifications is fraught with difficulty as many of these isofroms in low 
quantities will go unidentified and some of the modifications may have occurred ex-vivo 
following sampling [97]. A further small study assessing oxidised DJ-1 derived from 
erythrocytes found that 43 PD patients had significantly raised levels compared to 8 MSA 
patients, 13 PSP patients and 16 controls [98]. DJ-1 has also been assessed in saliva.  Once 
saliva composition and total protein content had been accounted, there were similar levels in 
16 PD cases and 22 controls in one study and 74 PD cases with 12 controls in a further study, 
with inconsistent correlation using various clinical scores of severity [99,100].  
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Lipid peroxidation changes secondary to oxidative stress: Reactive oxygen species have a clear 
affinity for lipids and the resulting lipid peroxidation can be considered a surrogate marker 
for oxidative stress. Malondialdehyde (MDA) is the most researched candidate and has been 
found to have significantly elevated levels in serum/plasma compared to controls 
consistently in study sizes of 20, 56 and 80 PD patients [101²103]. It also correlated inversely 
with disease progression in a much larger study of 211 PD patients and 135 controls [78]. 
Raised lipid hydroperoxides were also associated with late PD only [102]. However, this has 
not been replicated in CSF analysis of 21 PD patients and 20 controls [104]. 
 
Recently developments in metabolic profiling of many constituents involved in fatty acid 
oxidation have highlighted a number of decreased long chain acylcarnitines in early PD in 
studies involving 40 and 254 PD patients [105,106]. Previous studies have also shown other 
products of fatty acid oxidation such as F2-isoprostanes (F2-IsoPs), neuroprostanes (F4-NPs) 
and hydroxyeicosatetraenoic acid products (HETEs) being altered in PD but plasma levels of 
F2-IsoPs in PD subjects were not significantly different from controls in a study of 47 PD 
patients assessing plasma and a further similarly sized study assessing plasma and urine 
[107,108]. A third study subsequently showed plasma F2-IsoPs, F4-NPs and HETEs were 
significantly higher in 61 PD subjects compared to controls [79].  
 
Urate: Urate is a product of purine metabolism and is also an antioxidant present in both 
brain and blood. Urate was initially investigated as a potential biomarker when 
epidemiology studies found a link between high urate levels and a reduced risk of PD. A 
recent meta-analysis analysing all relevant epidemiological studies confirmed that high 
serum urate (defined as a serum urate above 6.8 mg/dl) is associated with a reduced risk of 
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PD by 33% in a dose-dependent manner [109]. This prompted further research as a 
biomarker and a further recent meta-analysis analysing all studies assessing serum urate 
and PD, amounting to 2379 PD patients and 2267 controls. Serum urate was significantly 
lower in PD patients than in controls with no geographic or differences between sex. Due to 
the variations in study designs it was difficult to correlate urate with PD severity but later 
stages appeared to have a more marked reduction still of urate levels compared to early or 
mild PD [110]. Urate levels may help to differentiated between PD and PSP or vascular 
parkinsonism, but not between PD and MSA [111]. 
 
Mitochondrial DNA: A Chinese study quantified mtDNA copy number in the serum of 414 
PD cases and 231 controls using real-time quantitative PCR. Mean mtDNa copy numbers 
were significantly decreased by around 40% compared to controls. In total 71% of PD 
patients exhibited a significant decrease of mtDNA copy number compared to controls. The 
mtDNA copy number also had a significant difference between age of onset in PD cases 
with 75% of cases with onset over the age of 50 having a significantly lowered mtDNA copy 
number compared to 49% of cases with onset less than 50 years. Interestingly, there was also 
a significant reduction in mtDNA copy number in patients with compound heterozygous 
POLG1 mutations [112].  
 
A further study assessed mtDNA copy number in the serum of 363 white blood cell samples, 
151 post mortem samples of substantia nigra pars compacta (SNpc) and 120 samples of 
frontal cortex in PD cases with matched controls for all samples. Quantitative PCR was use 
to assess mtDNA copy number. A significant decrease in mtDNA copy number in PD 
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patient blood cells independent of age and gender, and this was mirrored in the post 
mortem samples of SNpc and frontal cortex [113].  
 
Methylated mitochondrial DNA (mtDNA) was reported to be reduced in the CSF of 56 PD 
patients with no association between age, gender or clinical presentation and severity [114]. 
A further recent CSF study was able to differentiate iPD from PD caused by LRRK2 
mutations in that the 20 LRRK2 PD patients had markedly elevated levels of cell-free 
circulating mtDNA levels compared to 26 asymptomatic LRRK2 mutation carriers, 32 iPD 
patients and 21 controls [115].  
 
Summary and outlook: Currently, most of the work attempting to identify biomarkers 
reflecting mitochondrial dysfunction in PD identified viable candidates but any attempts to 
correlate these to disease severity and progression were inconsistent and replication in 
independent cohorts is typically lacking.  
 
Imaging mitochondrial dysfunction in PD 
Magnetic resonance spectroscopy (MRS) enables measurement of metabolites and hence 
investigation of cellular dysfunction non-invasively in humans in vivo. Whilst aspects of 
mitochondrial dysfunction may be captured using standard proton MRS, 31-phosphorus 
MRS (31P-MRS) is considered the optimal modality to assess mitochondrial function, because 
most of the resolved molecules of interest are central to cellular bioenergetics, namely 
adenosine triphosphate (ATP), phosphocreatine (PCr), and cytosolic inorganic phosphate 
(Pi). In addition to phosphates involved in energy transduction pathways, 31P-MRS allows 
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measurements of phosphomonoesters and phosphodiesters that are the anabolic precursors 
and catabolic products of membrane phospholipids, intracellular pH, and cytosolic 
magnesium. Various methods are employed for absolute quantification, each with their own 
advantages and limitations. Absolute quantification can be time-consuming, no one method 
is absolutely superior to the others and there are technical challenges, for example, relating 
to variation in T1 and T2 relaxation times. To circumvent some of these issues, results are 
often presented as ratios of the signal intensities of two metabolites acquired from the same 
spectrum. However, interpretation of ratios can also be complicated because changes can be 
due to variations in the numerator, the denominator, or both.   
Dynamic protocols can be used to investigate skeletal muscle bioenergetics and characterise 
metabolite changes following exercise. PCr kinetics are often reported because the rate at 
which PCr returns to resting state concentration after an exercise-induced decrease is 
considered a measure of mitochondrial oxidative capacity. Protocols applying the same 
principle to central nervous system areas, for example occipital lobe metabolite changes 
following visual stimulation, have been developed but are reported less frequently. In overt 
mitochondrial disease, such as mitochondrial cytopathies, ATP phosphorylation potential (a 
measure of the free energy of ATP) is diminished; this is associated with an elevation of Pi 
and calculated ADP as well as decreased PCr concentration [116]. Some authors have also 
hypothesised that dysfunctional mitochondria release Pi in the cytoplasm, where its 
concentration increases and can be measured by MRS [117]. 
 
31P-MRS has been applied to investigate bioenergetic dysfunction in PD in both muscle and 
brain. Early studies sought evidence of bioenergetic dysfunction in the skeletal muscle of PD 
patients with mixed results. One of these studies applied a dynamic protocol to assess the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
bioenergetics of digital flexors following exercise [118]. No statistically significant 
differences between seven patients and 11 healthy controls were found, although the 
authors reported a non-significant delay of PCr recovery. The following year, a study 
assessed resting spectra acquired from the forearm muscles of 28 patients and 28 healthy 
controls [119]. An elevated Pi/PCr ratio was detected, and interpreted as evidence of 
mitochondrial dysfunction, as similar findings had been reported in patients with 
mitochondrial disorders. As the investigators did not conduct an exercise protocol, PCr 
recovery kinetics could not be assessed. 
 
More recent studies have focused on the brain. In a comprehensive quantitative study, it 
was demonstrated that ATP and PCr concentrations were significantly reduced in the 
midbrain and putamen of 16 early and 13 late-stage PD patients compared to 19 healthy 
controls [120]. A relative decrease in ATP (reported as a percentage of the total phosphorus 
signal area) was found in another study [117] in the basal ganglia and brainstem of ten 
patients, compared to nine controls, and was interpreted as in vivo evidence of 
mitochondrial dysfunction. In contrast, a further study did not find any significant 
differences in 31P-MRS parameters in the brains of 20 patients with early PD compared to 12 
controls [121]. Interestingly, the authors of the latter study suggested that brain 
bioenergetics might be affected by oestrogen levels, as they found, in the same patient 
cohort, lower ATP concentrations in ten men with PD compared to ten women [122]. The 
discrepancy in the results might be ascribed to methodological and analysis differences. 
 
Metabolite alterations have also been reported in PD beyond the nigrostriatal tract. Pi has 
been shown to be elevated in the temporoparietal [117], occipital [123], and frontal [124] 
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lobes in PD. In the latter study, decreased phosphorylation potentials in ten patients 
compared to nine healthy controls were also detected. Further evidence for latent 
bioenergetic dysfunction in anatomical areas not considered primarily affected by the 
disease was provided by two studies from the same group [125,126]. The authors 
demonstrated that ATP and PCr concentrations in the occipital lobes remained constant 
during visual stimulation in both healthy controls and patients. However, in PD, the level of 
these metabolites decreased during the recovery phase, in contrast to an increase in healthy 
subjects. The authors concluded that mitochondrial dysfunction is unmasked during the 
post-activation period, hypothesising that this was a phase of particularly increased energy 
demand. The same group also showed that, in a patient with a compound heterozygous 
PINK1 mutation, basal levels of ATP and PCr in occipital cortex were decreased, the 
concentration of these metabolites dropped further during visual activation, and then 
recovered almost to resting levels during the post-activation period [126]. In contrast, a 
different group detected elevated PCr in the putamen of two homozygous PINK1 patients, 
and elevated ATP in one of them [127]. They also assessed nine heterozygous PINK1 
carriers, and found no changes in phosphorus metabolites compared to 23 healthy controls. 
It appears there may be heterogeneity in the metabolic phenotype of PD, and potentially 
genetic influences. 
 
Overall, to date, 31P-MRS studies have detected some evidence of bioenergetic dysfunction 
in vivo in PD, consistent with the experimental literature. However, there are at present only 
a limited number of studies, and great heterogeneity in terms of acquisition and analysis 
techniques. An important gap in the literature is that no longitudinal studies assessing 
variations of phosphorus spectra over time have yet been conducted. This is crucial to 
determine whether 31P-MRS could be used as a biomarker of progressive energy metabolic 
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failure, because the demonstration of target engagement by emerging therapies that 
influence mitochondrial biology in PD appears an exciting practical future application. 
 
Clinical trials with mitochondrial rescue agents 
The strong evidence of mitochondrial dysfunction in both sporadic PD and all forms of 
familial PD as well as in a multitude of different model systems has made the rescue of 
mitochondrial dysfunction an obvious target for neuroprotective intervention . In this final 
section, we will briefly discuss clinical trials which investigated compounds for their 
neuroprotective effect in PD patients, based on the assumption that these drugs would slow 
down neuronal cell death and thus disease progression by restoring energy production, 
reducing oxidative stress or both. 
 
Selegiline and tocopherol/vitamin E: The first trial investigating drugs with putative rescue 
mechanisms on mitochondrial function and oxidative stress was the DATATOP study [128]. 
25 years later, it is still a landmark study. Both selegiline as a monoamine oxidase B inhibitor 
at a dose of 10 mg per day and tocopherol (a component of vitamin E that traps free radicals) 
at a dose of 2000 IU per day were assessed together with two matched placebos in 800 
patients, randomly assigned to one of the four treatment arms. The primary endpoint was 
the onset of disability prompting the clinical decision to administer levodopa. The results of 
the tocopherol arm were clearly negative after a mean of 14 +/- 6 months. The selegiline 
treatment and matched placebo arms were extended up to 24 months. The use of selegiline 
had a beneficial effect which occurred largely during the first 12 months. The results and 
interpretation of the DATATOP study have been hotly debated but it is currently felt that 
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the apparent beneficial effect of selegiline medication is most likely to be due to its 
symptomatic effect rather than a neuroprotective effect.  
 
MitoQ and ubiquinone: MitoQ consists of the lipophilic cation triphenylphosphonium (TPP) 
covalently attached to the ubiquinone moiety of the edogenous antioxidant CoQ10 [129]. 
The TPP cation enables MitoQ to cross membranes and to accumulate several-hundred fold 
within mitochondria due to the large membrane potential [130]. A 13-centre in New Zealand 
and Australia recruited 128 newly diagnosed untreated patients with PD in a double-blind 
study of two doses of MitoQ compared with placebo. There was no difference in the UPDRS 
score at 12 month follow-up. The much larger QE3 study investigated the potential 
neuroprotective effect of ubiquinone (CoQ10) in 600 drug-naive participants with PD who 
were randomly assigned to receive placebo, 1200 mg/d or 2400 mg/d of CoQ10. All 
participants also received 1200 IU/d of vitamin E. Patients were observed for 16 months or 
until symptomatic treatment with dopaminergic medication was required. The study was 
powered to detect a 3-point difference between the active treatment and placebo. CoQ10 was 
safe and well tolerated but did not show any clinical benefit [131]. 
 
Creatine: Creatine acts as an energy source after conversion to phosphor-creatine. In one of 
the largest studies ever undertaken in PD, 1741 patients were recruited into two treatment 
arms, placebo vs creatine monohydrate at a dose of 10 g/d. Patients were followed up for an 
impressive minimum of 5 years with a maximum follow-up of 8 years. The trial was 
terminated early for futility based on the results of a planned interim analysis of participants 
enrolled at least 5 years prior to the date of the analysis (n=995). Creatine treatment did not 
improve the outcome in patients with early or treated PD [132].  
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Pioglitazone: Pioglitazone is an FDA-licensed drug for the treatment of type 2 diabetes. As a 
peroxisome proliferator-DFWLYDWHGUHFHSWRUǄ33$5-ǄDJRQLVWLWDFWVWRUHGXFHLQVXOLQ
resistance. Its co-factor PGC-ǂLVDWUDQVFULSWLRQDOFRDFWLYDWRUDQGRIWHQUHIHUUHGWRDVD 
mitochondrial master regulator. There is strong evidence of impaired PGC-ǂUHJXODWHG
transcriptional networks in PD [133]. 210 patients were enrolled in a phase 2, multicentre, 
double-blind, randomised, placebo-controlled, futility trial with three treatment arms, 
namely either 15 mg/day or 45 mg/day pioglitazone or placebo. The primary outcome was 
the change in total MDS-UPDRS score between baseline and 44 weeks. The results were 
negative and suggested that pioglitazone is unlikely to modify progression in early PD [134]. 
 
Exenatide: Exenatide a glucagon-like peptide-1 (GLP-1) agonist which is again licensed for 
the treatment of type 2 diabetes. Its precise mechanism in PD brains remains uncertain but 
preclinical data on GLP-1 agonists include reports of a protective effect in the MPTP-mouse 
model of PD and a stimulating effect on mitochondrial biogenesis in vitro [135,136]. A single-
centre, randomised, double-blind, placebo-controlled trial randomly assigned 62 patients 
with moderate PD to receive subcutaneous injections of 2 mg or placebo once weekly for 48 
weeks, followed by a 12-week washout period. At 60 weeks, off-medication scores on part 3 
of the MDS-UPDRS had improved by 1.0 points in the exenatide arm but worsened by 2.1 
points in the placebo group, an adjusted mean difference of -3.5 points in the practically 
defined off-stage [137].  
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Summary and outlook: The lack of a beneficial effect for all drugs described above other than 
exenatide made some authors question the rationale for targeting mitochondria and 
oxidative stress at all in PD [130]. However, negative data from one study only question the 
therapeutic usefulness of a specific compound at its best and at least some studies such as 
the MitoQ study appear underpowered as well. Furthermore, data on blood-brain barrier 
penetrance in PD patients is not consistently available for the tested compounds and none of 
these studies had a biomarker arm which would have confirmed target engagement. As 
described at the beginning of this article, there is strong evidence of mitochondrial 
dysfunction in both sporadic and all forms of genetic PD. General doubts about the 
relevance of mitochondrial rescue as a promising strategy for neuroprotection in PD are 
therefore ill justified.  
 
Conclusions and perspectives 
There is enormous momentum in the field of mitochondrial research in PD but the field also 
seems rather fragmented. It will be crucial to have better integration and meaningful 
translation from the bench to the bedside and back to make real progress. Our next goal has 
to be to identify those PD patients who have particularly marked mitochondrial dysfunction 
and then develop mitochondrial biomarkers which correlate with disease progression and 
provide evidence of target engagement for putative mitochondrial rescue agents in future 
clinical trials.  
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&ŝŐƵƌĞ ? ?DŝƚŽĐŚŽŶĚƌŝĂůĂďŶŽƌŵĂůŝƚŝĞƐŝŶWĂƌŬŝŶƐŽŶ ?ƐŝƐĞĂƐĞ ? Central to several subtypes of PD are 
abnormalities of the mitochondria. Cells and/or animal models with mutations or reduction in the 
protein levels of Parkin, PINK1 and DJ1 typically develop a complex I defect resulting in reduced ATP 
production; whereas LRRK2 mutations result in reduced complex IV activity, again resulting in ATP 
levels. Reductions in the mitochondrial membrane potential (MMP), aberrations in the mitophagy 
pathway and disturbed mitochondrial morphology have also been demonstrated as a consequence 
of impaired function for all of the above genes.  
 
References 
1 Nunnari J & Suomalainen A (2012) Mitochondria: In Sickness and in Health. Cell 148, 1145²
1159. 
2 Ballard PA, Tetrud JW & Langston JW (1985) Permanent human parkinsonism due to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35, 949²56. 
3 Nomoto M, Kaseda S, Iwata S, Shimizu T, Fukuda T & Nakagawa S (2000) The metabolic 
rate and vulnerability of dopaminergic neurons, and adenosine dynamics in the 
cerebral cortex, nucleus accumbens, caudate nucleus, and putamen of the common 
marmoset. J. Neurol. 247 Suppl 5, V16-22. 
4 Haddad D & Nakamura K (2015) Understanding the susceptibility of dopamine neurons to 
PLWRFKRQGULDOVWUHVVRUVLQ3DUNLQVRQ·VGLVHDVHFEBS Lett. 589, 3702²3713. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
5 Pacelli C, Giguère N, Bourque M-J, Lévesque M, Slack RS & Trudeau L-É (2015) Elevated 
Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the 
Vulnerability of Dopamine Neurons. Curr. Biol. 25, 2349²2360. 
6 Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB & Marsden CD (1989) 
Mitochondrial complH[,GHILFLHQF\LQ3DUNLQVRQ·VGLVHDVHLancet (London, England) 1, 
1269. 
7 Parker WD, Boyson SJ & Parks JK (1989) Abnormalities of the electron transport chain in 
LGLRSDWKLFSDUNLQVRQ·VGLVHDVHAnn. Neurol. 26, 719²723. 
8 Bose A & Beal MF (2016) MitochonGULDOG\VIXQFWLRQLQ3DUNLQVRQ·VGLVHDVHJ. Neurochem. 
139, 216²231. 
9 Mortiboys H, Thomas KJ, Koopman WJH, Klaffke S, Abou-Sleiman P, Olpin S, Wood NW, 
Willems PHGM, Smeitink JAM, Cookson MR & Bandmann O (2008) Mitochondrial 
function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 64, 
555²65. 
10 Vincent A, Briggs L, Chatwin GFJ, Emery E, Tomlins R, Oswald M, Middleton CA, Evans 
GJO, Sweeney ST & Elliott CJH (2012) parkin-induced defects in neurophysiology and 
locomotion are generated by metabolic dysfunction and not oxidative stress. Hum. Mol. 
Genet. 21, 1760²1769. 
11 Flinn L, Mortiboys H, Volkmann K, Koster RW, Ingham PW & Bandmann O (2009) 
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish 
(Danio rerio). Brain 132, 1613²1623. 
12 Nguyen TN, Padman BS & Lazarou M (2016) Deciphering the Molecular Signals of 
PINK1/Parkin Mitophagy. Trends Cell Biol. 26, 733²744. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
13 Girotto S, Sturlese M, Bellanda M, Tessari I, Cappellini R, Bisaglia M, Bubacco L & 
Mammi S (2012) Dopamine-derived quinones affect the structure of the redox sensor 
DJ-1 through modifications at Cys-106 and Cys-53. J. Biol. Chem. 287, 18738²49. 
14 Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G & 
Zhu X (2012) LRRK2 regulates mitochondrial dynamics and function through direct 
interaction with DLP1. Hum. Mol. Genet. 21, 1931²44. 
15 Lee J-W & Cannon JR (2015) LRRK2 mutations and neurotoxicant susceptibility. Exp. Biol. 
Med. (Maywood). 240, 752²9. 
16 Wallings R, Manzoni C & Bandopadhyay R (2015) Cellular processes associated with 
LRRK2 function and dysfunction. FEBS J. 282, 2806²26. 
17 Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C & Bandmann O (2015) UDCA 
exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in 
vivo. Neurology 85, 846²52. 
18 Papkovskaia TD, Chau K-Y, Inesta-Vaquera F, Papkovsky DB, Healy DG, Nishio K, 
Staddon J, Duchen MR, Hardy J, Schapira AH V & Cooper JM (2012) G2019S leucine-
rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. 
Hum. Mol. Genet. 21, 4201²13. 
19 Grünewald A, Arns B, Meier B, Brockmann K, Tadic V & Klein C (2014) Does uncoupling 
protein 2 expression qualify as marker of disease status in LRRK2-associated 
ParkLQVRQ·VGLVHDVH"Antioxid. Redox Signal. 20, 1955²60. 
20 Busiello RA, Savarese S & Lombardi A (2015) Mitochondrial uncoupling proteins and 
energy metabolism. Front. Physiol. 6, 36. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
21 Mortiboys H, Johansen KK, Aasly JO & Bandmann O (2010) Mitochondrial impairment in 
patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 
2017²2020. 
22 Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, 
Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean 
PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ & Melrose HL (2015) Progressive 
dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in 
mice. Neurobiol. Dis. 78, 172²95. 
23 Chaban Y, Boekema EJ & Dudkina N V. (2014) Structures of mitochondrial oxidative 
phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim. 
Biophys. Acta - Bioenerg. 1837, 418²426. 
24 Lapuente-Brun E, Moreno-Loshuertos R, Acin-Perez R, Latorre-Pellicer A, Colas C, Balsa 
E, Perales-Clemente E, Quiros PM, Calvo E, Rodriguez-Hernandez MA, Navas P, Cruz 
R, Carracedo A, Lopez-Otin C, Perez-Martos A, Fernandez-Silva P, Fernandez-Vizarra 
E & Enriquez JA (2013) Supercomplex Assembly Determines Electron Flux in the 
Mitochondrial Electron Transport Chain. Science (80-. ). 340, 1567²1570. 
25 Lopez-Fabuel I, Martin-Martin L, Resch-Beusher M, Azkona G, Sanchez-Pernaute R & 
%RODxRV-30LWRFKRQGULDOUHVSLUDWRU\FKDLQGLVRUJDQL]DWLRQLQ3DUNLQVRQ·V
disease-relevant PINK1 and DJ1 mutants. Neurochem. Int. 
26 Flinn LJ, Keatinge M, Bretaud S, Mortiboys H, Matsui H, De Felice E, Woodroof HI, 
Brown L, McTighe A, Soellner R, Allen CE, Heath PR, Milo M, Muqit MMK, Reichert 
AS, Köster RW, Ingham PW & Bandmann O (2013) TigarB causes mitochondrial 
dysfunction and neuronal loss in PINK1 deficiency. Ann. Neurol. 74, 837²847. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
27 Soman S, Keatinge M, Moein M, Da Costa M, Mortiboys H, Skupin A, Sugunan S, Bazala 
M, Kuznicki J & Bandmann O (2017) Inhibition of the mitochondrial calcium uniporter 
rescues dRSDPLQHUJLFQHXURQVLQSLQNïï]HEUDILVKEur. J. Neurosci. 45, 528²535. 
28 Yakes FM & Van Houten B (1997) Mitochondrial DNA damage is more extensive and 
persists longer than nuclear DNA damage in human cells following oxidative stress. 
Proc. Natl. Acad. Sci. U. S. A. 94, 514²9. 
29 Sanders LH, McCoy J, Hu X, Mastroberardino PG, Dickinson BC, Chang CJ, Chu CT, Van 
Houten B & Greenamyre JT (2014) Mitochondrial DNA damage: Molecular marker of 
YXOQHUDEOHQLJUDOQHXURQVLQ3DUNLQVRQ·VGLVHDVHNeurobiol. Dis. 70, 214²223. 
30 Coxhead J, Kurzawa-Akanbi M, Hussain R, Pyle A, Chinnery P & Hudson G (2016) 
6RPDWLFPW'1$YDULDWLRQLVDQLPSRUWDQWFRPSRQHQWRI3DUNLQVRQ·VGLVHDVHNeurobiol. 
Aging 38, 217.e1-217.e6. 
31 Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson 
JS, Betts J, Klopstock T, Taylor RW & Turnbull DM (2006) High levels of mitochondrial 
DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 
38, 515²517. 
32 Dölle C, Flønes I, Nido GS, Miletic H, Osuagwu N, Kristoffersen S, Lilleng PK, Larsen JP, 
Tysnes O-B, Haugarvoll K, Bindoff LA & Tzoulis C (2016) Defective mitochondrial 
DNA homeostasis in the substantia nigra in Parkinson disease. Nat. Commun. 7, 13548. 
33 Palmer CS, Osellame LD, Stojanovski D & Ryan MT (2011) The regulation of 
mitochondrial morphology: Intricate mechanisms and dynamic machinery. Cell. Signal. 
23, 1534²1545. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
34 Lach B, Grimes D, Benoit B & Minkiewicz-Janda A (1992) Caudate nucleus pathology in 
3DUNLQVRQ·VGLVHDVHXOWUDVWUXctural and biochemical findings in biopsy material. Acta 
Neuropathol. 83, 352²60. 
35 Ahlqvist G, Landin S & Wroblewski R (1975) Ultrastructure of skeletal muscle in patients 
ZLWK3DUNLQVRQ·VGLVHDVHDQGXSSHUPRWRUOHVLRQVLab. Invest. 32, 673²9. 
36 Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, 
Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, 
Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, 
Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N 
& Okano H (2012) Mitochondrial dysfunction associated with increased oxidative stress 
DQGǂ-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain 
tissue. Mol. Brain 5, 35. 
37 Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB & Pallanck LJ (2003) 
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin 
mutants. Proc. Natl. Acad. Sci. U. S. A. 100, 4078²83. 
38 Wiemerslage L, Ismael S & Lee D (2016) Early alterations of mitochondrial morphology in 
GRSDPLQHUJLFQHXURQVIURP3DUNLQVRQ·VGLVHDVH-like pathology and time-dependent 
neuroprotection with D2 receptor activation. Mitochondrion 30, 138²147. 
39 Ramonet D, Daher JPL, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, 
Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, 
Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL & Moore DJ 
(2011) Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic 
Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS One 6, 
e18568. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
40 Cherra SJ, Steer E, Gusdon AM, Kiselyov K & Chu CT (2013) Mutant LRRK2 Elicits 
Calcium Imbalance and Depletion of Dendritic Mitochondria in Neurons. Am. J. Pathol. 
182, 474²484. 
41 Uo T, Dworzak J, Kinoshita C, Inman DM, Kinoshita Y, Horner PJ & Morrison RS (2009) 
Drp1 levels constitutively regulate mitochondrial dynamics and cell survival in cortical 
neurons. Exp. Neurol. 218, 274²285. 
42 Su Y-C & Qi X (2013) Inhibition of excessive mitochondrial fission reduced aberrant 
autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 
22, 4545²4561. 
43 Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA & Guo M (2006) 
Drosophila pink1 is required for mitochondrial function and interacts genetically with 
parkin. Nature 441, 1162²1166. 
44 Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim J-M & Chung J 
(2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by 
parkin. Nature 441, 1157²61. 
45 Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, 
Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe J-F, Saeki Y, Tanaka K & Matsuda 
N (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510, 162²6. 
46 Wang H, Song P, Du L, Tian W, Yue W, Liu M, Li D, Wang B, Zhu Y, Cao C, Zhou J & 
Chen Q (2011) Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation. J. 
Biol. Chem. 286, 11649²11658. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
47 Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ & 
Schwarz TL (2011) PINK1 and Parkin Target Miro for Phosphorylation and 
Degradation to Arrest Mitochondrial Motility. Cell 147, 893²906. 
48 Tang BL (2015) MIRO GTPases in Mitochondrial Transport, Homeostasis and Pathology. 
Cells 5. 
49 Hsieh C-H, Shaltouki A, Gonzalez AE, Bettencourt da Cruz A, Burbulla LF, St. Lawrence 
E, Schüle B, Krainc D, Palmer TD & Wang X (2016) Functional Impairment in Miro 
Degradation and Mitophagy Is a Shared Feature in FamiliDODQG6SRUDGLF3DUNLQVRQ·V
Disease. Cell Stem Cell 19, 709²724. 
&RURQD-&	'XFKHQ0533$5ǄDQG3*&-ǂDVWKHUDSHXWLFWDUJHWVLQ3DUNLQVRQ·V
Neurochem. Res. 40, 308²16. 
51 Ye Q, Huang W, Li D, Si E, Wang J, Wang Y, Chen C & Chen X (2016) Overexpression of 
PGC-ǂ,QIOXHQFHV0LWRFKRQGULDO6LJQDO7UDQVGXFWLRQRf Dopaminergic Neurons. Mol. 
Neurobiol. 53, 3756²3770. 
52 Ebrahim AS, Ko L-W & Yen S-H (2010) Reduced expression of peroxisome-proliferator 
activated receptor gamma coactivator-1alpha enhances alpha-synuclein 
oligomerization and down regulates AKT/GSK3beta signaling pathway in human 
neuronal cells that inducibly express alpha-synuclein. Neurosci. Lett. 473, 120²5. 
53 Deas E, Wood NW & Plun-)DYUHDX+0LWRSKDJ\DQG3DUNLQVRQ·VGLVHDVHWKH
PINK1-parkin link. Biochim. Biophys. Acta 1813, 623²33. 
54 de VULHV5/$	3U]HGERUVNL60LWRSKDJ\DQG3DUNLQVRQ·VGLVHDVH%HHDWHQWRVWD\
healthy. Mol. Cell. Neurosci. 55, 37²43. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
55 Hattori N, Saiki S & Imai Y (2014) Regulation by mitophagy. Int. J. Biochem. Cell Biol. 53, 
147²150. 
56 Ryan BJ, Hoek S, Fon EA & Wade-Martins R (2015) Mitochondrial dysfunction and 
PLWRSKDJ\LQ3DUNLQVRQ·VIURPIDPLOLDOWRVSRUDGLFGLVHDVHTrends Biochem. Sci. 40, 
200²210. 
57 Sheng Z-H & Cai Q (2012) Mitochondrial transport in neurons: impact on synaptic 
homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13, 77²93. 
58 Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, Miller CCJ, 
Whitworth AJ & De Vos KJ (2014) Increasing microtubule acetylation rescues axonal 
transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat. 
Commun. 5, 5245. 
59 Esteves AR, Gozes I & Cardoso SM (2014) The rescue of microtubule-dependent traffic 
UHFRYHUVPLWRFKRQGULDOIXQFWLRQLQ3DUNLQVRQ·VGLVHDVHBiochim. Biophys. Acta - Mol. 
Basis Dis. 1842, 7²21. 
60 Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, 
'HOO·$TXLOD&'H0DUL0)HUUDQLQL(%RQLIDWL93DFHOOL&	&RFFR7(IIHFWRI
resveratrol on mitochondrial function: Implications in parkin-associated familiar 
ParNLQVRQ·VGLVHDVHBiochim. Biophys. Acta - Mol. Basis Dis. 1842, 902²915. 
61 Peng J, Liu Q, Rao MS & Zeng X (2013) Using Human Pluripotent Stem Cell²Derived 
'RSDPLQHUJLF1HXURQVWR(YDOXDWH&DQGLGDWH3DUNLQVRQ·V'LVHDVH7KHUDSHXWLF$JHQWV
in MPP + and Rotenone Models. J. Biomol. Screen. 18, 522²533. 
62 Mortiboys H, Aasly J & Bandmann O (2013) Ursocholanic acid rescues mitochondrial 
IXQFWLRQLQFRPPRQIRUPVRIIDPLOLDO3DUNLQVRQ·VGLVHDVHBrain 136, 3038²3050. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
63 Chun HS & Low WC (2012) Ursodeoxycholic acid suppresses mitochondria-dependent 
programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology 
292, 105²112. 
64 Fonseca I, Gordino G, Moreira S, Nunes MJ, Azevedo C, Gama MJ, Rodrigues E, 
Rodrigues CMP & Castro-Caldas M (2017) Tauroursodeoxycholic Acid Protects Against 
Mitochondrial Dysfunction and Cell Death via Mitophagy in Human Neuroblastoma 
Cells. Mol. Neurobiol. 54, 6107²6119. 
65 Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CMP, 
Alfonso A, Steer C, Liu L, Przedborski S & Wolozin B (2005) Similar Patterns of 
0LWRFKRQGULDO9XOQHUDELOLW\DQG5HVFXH,QGXFHGE\*HQHWLF0RGLILFDWLRQRIǂ-
Synuclein, Parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655²42668. 
66 Debattisti V, Pendin D, Ziviani E, Daga A & Scorrano L (2014) Reduction of endoplasmic 
reticulum stress attenuates the defects caused by Drosophila mitofusin depletion. J. Cell 
Biol. 204, 303²12. 
67 Abdelkader NF, Safar MM & Salem HA (2016) Ursodeoxycholic Acid Ameliorates 
Apoptotic &DVFDGHLQWKH5RWHQRQH0RGHORI3DUNLQVRQ·V'LVHDVH0RGXODWLRQRI
Mitochondrial Perturbations. Mol. Neurobiol. 53, 810²7. 
68 Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CMP & 
Gama MJ (2012) Tauroursodeoxycholic Acid Prevents MPTP-Induced Dopaminergic 
&HOO'HDWKLQD0RXVH0RGHORI3DUNLQVRQ·V'LVHDVHMol. Neurobiol. 46, 475²486. 
69 Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk 
CB, Maxwell MM, Rochet J-C, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
BT & Kazantsev AG (2007) Sirtuin 2 Inhibitors Rescue  -Synuclein-Mediated Toxicity in 
0RGHOVRI3DUNLQVRQ·V'LVHDVHScience (80-. ). 317, 516²519. 
70 Yoon IS, Au Q, Barber JR, Ng SC & Zhang B (2010) Development of a high-throughput 
screening assay for cytoprotective agents in rotenone-induced cell death. Anal. Biochem. 
407, 205²210. 
71 Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu 
F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, 
Caldwell GA, McCaffery JM, Rochet J-C & Lindquist S (2010) Compounds from an 
unbiased chemical screen reverse both ER-to-Golgi trafficking defects and 
PLWRFKRQGULDOG\VIXQFWLRQLQ3DUNLQVRQ·VGLVHDVHPRGHOVDis. Model. Mech. 3, 194²208. 
72 Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG & Montine TJ (1999) 
3DUNLQVRQ·V'LVHDVH,V$VVRFLDWHGZLWK2[LGDWLYH'DPDJHWR&\WRSODVPLF'1$DQG
RNA in Substantia Nigra Neurons. Am. J. Pathol. 154, 1423²1429. 
73 Abe T, Isobe C, Murata T, Sato C & Tohgi H (2003) Alteration of 8-hydroxyguanosine 
FRQFHQWUDWLRQVLQWKHFHUHEURVSLQDOIOXLGDQGVHUXPIURPSDWLHQWVZLWK3DUNLQVRQ·V
disease. Neurosci. Lett. 336, 105²8. 
74 Zerr I, Gawinecka J & Gmitterowa K (2009) P2.028 8-OHdG in cerebrospinal fluid as a 
marker of oxidative stress in various neurodegenerative diseases. Parkinsonism Relat. 
Disord. 15, S96. 
75 Isobe C, Abe T & Terayama Y (2010) Levels of reduced and oxidized coenzymeQ-10 and 
8-hydroxy-Ļ-deoxyguanosine in the cerebrospinal fluid of patients with living 
3DUNLQVRQ·VGLVHDVHGHPRQVWUDWHWKDWPLWRFKRQGULDOR[LGDWLYHGDPDJHDQGRU
oxidative DNA damage contributes to the neurodegenera. Neurosci. Lett. 469, 159²163. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
76 Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, 
Castellani RJ, Perry G, Smith MA & Itoyama Y (2002) Systemic Increase of Oxidative 
1XFOHLF$FLG'DPDJHLQ3DUNLQVRQ·V'LVHDVHDQG0XOWLSOH6\VWHP$WURSK\Neurobiol. 
Dis. 9, 244²248. 
77 Abe T, Tohgi H, Isobe C, Murata T & Sato C (2002) Remarkable increase in the 
concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with 
$O]KHLPHU·VGLVHDVHJ. Neurosci. Res. 70, 447²450. 
78 Chen C-M, Liu J-L, Wu Y-R, Chen Y-C, Cheng H-S, Cheng M-L & Chiu DT (2009) 
Increased oxidative damage in peripheral blood corUHODWHVZLWKVHYHULW\RI3DUNLQVRQ·V
disease. Neurobiol. Dis. 33, 429²435. 
79 Seet RCS, Lee C-YJ, Lim ECH, Tan JJH, Quek AML, Chong W-L, Looi W-F, Huang S-H, 
Wang H, Chan Y-H & Halliwell B (2010) Oxidative damage in Parkinson disease: 
Measurement using accurate biomarkers. Free Radic. Biol. Med. 48, 560²566. 
80 Sato S, Mizuno Y & Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a 
biomarker for progression of Parkinson disease. Neurology 64, 1081²1083. 
81 VALAVANIDIS A, VLACHOGIANNI T & FIOTAKIS C (2009) 8-hydroxy-Ļ-
deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and 
Carcinogenesis. J. Environ. Sci. Heal. Part C 27, 120²139. 
/H:LWW3$/L-/X0%HDFK7*$GOHU&+*XR/	$UL]RQD3DUNLQVRQ·V'LVHDVH
Consortium (2013) 3-hydrR[\N\QXUHQLQHDQGRWKHU3DUNLQVRQ·VGLVHDVHELRPDUNHUV
discovered by metabolomic analysis. Mov. Disord. 28, 1653²1660. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
83 Konings CH, Kuiper MA, Teerlink T, Mulder C, Scheltens P & Wolters EC (1999) Normal 
cerebrospinal fluid glutathione concentrations in 3DUNLQVRQ·VGLVHDVH$O]KHLPHU·V
disease and multiple system atrophy. J. Neurol. Sci. 168, 112²5. 
84 Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M & Chazot G (2007) Peripheral Blood 
0DUNHUVRI2[LGDWLYH6WUHVVLQ3DUNLQVRQ·V'LVHDVHEur. Neurol. 58, 78²83. 
*|NoHdRNDO%<XUWGDü0.HVNLQ*OHU6*QHü+1$WDo8oDU&$\WDo%'XUDN=(
<ROGDü7.'XUDNú	dXEXNoX+&6HUXPJOXWDWKLRQHSHUR[LGDVH[DQWKLQH
oxidase, and superoxide dismutase activities and malondialdehyde levels in patients 
witK3DUNLQVRQ·VGLVHDVHNeurol. Sci. 38, 425²431. 
86 Shi M, Bradner J, Bammler TK, Eaton DL, Zhang J, Ye Z, Wilson AM, Montine TJ, Pan C 
& Zhang J (2009) Identification of glutathione S-transferase pi as a protein involved in 
Parkinson disease progression. Am. J. Pathol. 175, 54²65. 
87 Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn 
TA, Roher AE & Consortium AP (2012) Cerebrospinal fluid biomarkers of 
QHXURSDWKRORJLFDOO\GLDJQRVHG3DUNLQVRQ·VGLVHDVHVXEMHFWVNeurol. Res. 34, 669²676. 
88 Clements CM, McNally RS, Conti BJ, Mak TW & Ting JP-Y (2006) DJ-1, a cancer- and 
3DUNLQVRQ·VGLVHDVH-associated protein, stabilizes the antioxidant transcriptional master 
regulator Nrf2. Proc. Natl. Acad. Sci. 103, 15091²15096. 
89 Chen J, Li L & Chin L-S (2010) Parkinson disease protein DJ-1 converts from a zymogen to 
a protease by carboxyl-terminal cleavage. Hum. Mol. Genet. 19, 2395²2408. 
90 Junn E, Jang WH, Zhao X, Jeong BS & Mouradian MM (2009) Mitochondrial localization 
of DJ-1 leads to enhanced neuroprotection. J. Neurosci. Res. 87, 123²129. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
91 Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T & 
Hashimoto M (2006) Increased level of DJ-1 in the cerebrospinal fluids of sporadic 
3DUNLQVRQ·VGLVHDVHBiochem. Biophys. Res. Commun. 345, 967²972. 
92 Herbert MK, Eeftens JM, Aerts MB, Esselink RAJ, Bloem BR, Kuiperij HB & Verbeek MM 
(2014) CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and 
controls. Park. Relat. Disord. 20, 112²115. 
93 Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, 
Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, 
Jensen PH & Zhang J (2010) DJ-DQGǂ-synuclein in human cerebrospinal fluid as 
ELRPDUNHUVRI3DUNLQVRQ·VGLsease. Brain 133, 713²726. 
94 Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F 
& Hashimoto M (2007) Plasma levels of DJ-1 as a possible marker for progression of 
VSRUDGLF3DUNLQVRQ·VGLVHDVHNeurosci. Lett. 425, 18²22. 
95 Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, Maita H, Iguchi-Ariga SMM, Sasaki H & 
Ariga H (2008) Secretion of DJ-LQWRWKHVHUXPRISDWLHQWVZLWK3DUNLQVRQ·VGLVHDVH
Neurosci. Lett. 431, 86²89. 
96 Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, 
Peskind ER, Galasko D, Jankovic J, Leverenz JB & Zhang J (2010) Significance and 
confounders of peripheral DJ-1 and alpha-V\QXFOHLQLQ3DUNLQVRQ·VGLVHDVHNeurosci. 
Lett. 480, 78²82. 
97 Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu S-C, Cain KC, Pan C, Edgar JS, 
Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M & Zhang J (2012) DJ-1 
isoforms in whole blood as potential biomarkers of Parkinson disease. Sci. Rep. 2, 954. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
98 Yamagishi Y, Saigoh K, Saito Y, Ogawa I, Mitsui Y, Hamada Y, Samukawa M, Suzuki H, 
.XZDKDUD0+LUDQR01RJXFKL1	.XVXQRNL6'LDJQRVLVRI3DUNLQVRQ·V
disease and the level of oxidized DJ-1 protein. Neurosci. Res. 
99 Masters JM, Noyce AJ, Warner TT, Giovannoni G & Proctor GB (2015) Elevated salivary 
SURWHLQLQ3DUNLQVRQ·VGLVHDVHDQGVDOLYDU\'--1 as a potential marker of disease 
severity. Parkinsonism Relat. Disord. 21, 1251²1255. 
100 Kang W-Y, Yang Q, Jiang X-F, Chen W, Zhang L-Y, Wang X-Y, Zhang L-N, Quinn TJ, 
Liu J & Chen S-D (2014) Salivary DJ-FRXOGEHDQLQGLFDWRURI3DUNLQVRQ·VGLVHDVH
progression. Front. Aging Neurosci. 6, 102. 
101 Sharma A, Kaur P, Kumar B, Prabhakar S & Gill KD (2008) Plasma lipid peroxidation 
DQGDQWLR[LGDQWVWDWXVRI3DUNLQVRQ·VGLVHDVHSDWLHQWVLQWKH,QGLan population. 
Parkinsonism Relat. Disord. 14, 52²7. 
102 de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, 
Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, Lavado EL, Moreira EG 
& Barbosa DS (2016) Highly specific changes in antioxidant levels and lipid 
SHUR[LGDWLRQLQ3DUNLQVRQ·VGLVHDVHDQGLWVSURJUHVVLRQ'LVHDVHDQGVWDJLQJ
biomarkers and new drug targets. Neurosci. Lett. 617, 66²71. 
103 Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC & 
5DR953ODVPDOHYHOVRIOLSLGSHUR[LGHVLQSDWLHQWVZLWK3DUNLQVRQ·VGLVHDVH
Eur. Rev. Med. Pharmacol. Sci. 13, 129²32. 
104 Shukla R, Rajani M, Srivastava N, Barthwal MK & Dikshit M (2006) Nitrite and 
malondialdehyde content in cerebrospinal IOXLGRISDWLHQWVZLWK3DUNLQVRQ·VGLVHDVH
Int. J. Neurosci. 116, 1391²402. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
105 Burté F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, Yu-Wai-Man P, Burn DJ, 
Santibanez-.RUHI0	+XGVRQ*PHWDEROLFSURILOLQJRI3DUNLQVRQ·VGLVHDVHDQG
mild cognitive impairment. Mov. Disord. 32, 927²932. 
106 Saiki S, Hatano T, Fujimaki M, Ishikawa K-I, Mori A, Oji Y, Okuzumi A, Fukuhara T, 
Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K & 
Hattori N (2017) Decreased long-chain acylcarnitinHVIURPLQVXIILFLHQWǃ-oxidation as 
SRWHQWLDOHDUO\GLDJQRVWLFPDUNHUVIRU3DUNLQVRQ·VGLVHDVHSci. Rep. 7, 7328. 
107 Irizarry MC, Yao Y, Hyman BT, Growdon JH & Praticò D (2007) Plasma F2A Isoprostane 
/HYHOVLQ$O]KHLPHU·VDQG3DUNLQVRQ·V'LVHDVHNeurodegener. Dis. 4, 403²405. 
108 Connolly J, Siderowf A, Clark CM, Mu D & Pratico D (2008) F2 Isoprostane Levels in 
Plasma and Urine do not Support Increased Lipid Peroxidation in Cognitively 
Impaired Parkinson Disease Patients. Cogn. Behav. Neurol. 21, 83²86. 
6KHQ&*XR</XR:/LQ&	'LQJ06HUXPXUDWHDQGWKHULVNRI3DUNLQVRQ·V
disease: results from a meta-analysis. Can. J. Neurol. Sci. 40, 73²9. 
110 Wen M, Zhou B, Chen Y-H, Ma Z-L, Gou Y, Zhang C-L, Yu W-F & Jiao L (2017) Serum 
uric acid leveOVLQSDWLHQWVZLWK3DUNLQVRQ·VGLVHDVH$PHWD-analysis. PLoS One 12, 
e0173731. 
111 Pan M, Gao H, Long L, Xu Y, Liu M, Zou J, Wu A, Wei X, Chen X, Tang B & Wang Q 
6HUXPXULFDFLGLQSDWLHQWVZLWK3DUNLQVRQ·VGLVHDVHDQGYDVFXODUSDUNLQVRQLVP
a cross-sectional study. Neuroimmunomodulation 20, 19²28. 
112 Gui Y-X, Xu Z-P, Lv W, Zhao J-J & Hu X-Y (2015) Evidence for polymerase gamma, 
32/*YDULDWLRQLQUHGXFHGPLWRFKRQGULDO'1$FRS\QXPEHULQ3DUNLQVRQ·VGLVHDVH
Parkinsonism Relat. Disord. 21, 282²286. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
113 Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D & Hudson G (2016) 
5HGXFHGPLWRFKRQGULDO'1$FRS\QXPEHULVDELRPDUNHURI3DUNLQVRQ·VGLVHDVH
Neurobiol. Aging 38, 216.e7-216.e10. 
114 Pyle A, Brennan R, Kurzawa-Akanbi M, Yarnall A, Thouin A, Mollenhauer B, Burn D, 
Chinnery PF & Hudson G (2015) Reduced cerebrospinal fluid mitochondrial DNA is a 
biomarker for early-VWDJH3DUNLQVRQ·VGLVHDVHAnn. Neurol. 78, 1000²1004. 
115 Podlesniy P, Vilas D, Taylor P, Shaw LM, Tolosa E & Trullas R (2016) Mitochondrial 
'1$LQ&6)GLVWLQJXLVKHV/55.IURPLGLRSDWKLF3DUNLQVRQ·VGLVHDVHNeurobiol. Dis. 
94, 10²17. 
116 Barbiroli B, Montagna P, Martinelli P, Lodi R, Iotti S, Cortelli P, Funicello R & Zaniol P 
(1993) Defective Brain Energy Metabolism Shown by in vivo 31 P MR Spectroscopy in 28 
Patients with Mitochondrial Cytopathies. J. Cereb. Blood Flow Metab. 13, 469²474. 
117 Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbé C, Cunningham VJ, Koepp 
MJ, Hammers A, Morris RG, Turjanski N & Brooks DJ (2000) Cortical dysfunction in 
non-GHPHQWHG3DUNLQVRQ·VGLVHDVHSDWLHQWVDFRPELQHG3-MRS and (18)FDG-PET 
study. Brain 123 ( Pt 2, 340²52. 
118 Taylor DJ, Krige D, Barnes PR, Kemp GJ, Carroll MT, Mann VM, Cooper JM, Marsden 
CD & Schapira AH (1994) A 31P magnetic resonance spectroscopy study of 
PLWRFKRQGULDOIXQFWLRQLQVNHOHWDOPXVFOHRISDWLHQWVZLWK3DUNLQVRQ·VGLVHDVHJ. Neurol. 
Sci. 125, 77²81. 
119 Penn AM, Roberts T, Hodder J, Allen PS, Zhu G & Martin WR (1995) Generalized 
mitochondrial dysfunction in ParkinsRQ·VGLVHDVHGHWHFWHGE\PDJQHWLFUHVRQDQFH
spectroscopy of muscle. Neurology 45, 2097²9. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
120 Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F & 
Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates 
PLWRFKRQGULDOG\VIXQFWLRQLQHDUO\DQGDGYDQFHG3DUNLQVRQ·VGLVHDVHBrain 132, 3285²
3297. 
121 Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC & Henchcliffe C (2015) 
Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of 
3DUNLQVRQ·V'LVHDVHJ. Neuroimaging 25, 105²110. 
122 Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC & Henchcliffe C (2014) Sex 
GLIIHUHQFHVLQFHUHEUDOHQHUJ\PHWDEROLVPLQ3DUNLQVRQ·VGLVHDVH$SKRVSKRUXV
magnetic resonance spectroscopic imaging study. Parkinsonism Relat. Disord. 20, 545²
548. 
123 Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P & Montagna P (1999) 
Phosphorus magnetic resonance spectroscopy in multiple system atrophy and 
3DUNLQVRQ·VGLVHDVHMov. Disord. 14, 430²5. 
124 Montagna P, Pierangeli G, Cortelli P, Zaniol P, Funicello R, Lugaresi E & Barbiroli B 
%UDLQ2[LGDWLYH0HWDEROLVPLQ3DUNLQVRQ·V'LVHDVH6WXGLHGE\3KRVSKRUXV
Magnetic Resonance Spectroscopy. J. Neuroimaging 3, 225²228. 
125 Rango M, BoniIDWL&	%UHVROLQ13DUNLQVRQ·V'LVHDVHDQG%UDLQ0LWRFKRQGULDO
Dysfunction: A Functional Phosphorus Magnetic Resonance Spectroscopy Study. J. 
Cereb. Blood Flow Metab. 26, 283²290. 
126 Rango M, Arighi A, Marotta G, Ronchi D & Bresolin N (2013) PINK1 parkinsonism and 
Parkinson disease: distinguishable brain mitochondrial function and metabolomics. 
Mitochondrion 13, 59²61. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
127 Hilker R, Pilatus U, Eggers C, Hagenah J, Roggendorf J, Baudrexel S, Klein JC, Neumaier 
B, Fink GR, Steinmetz H, Klein C & Hattingen E (2012) The Bioenergetic Status Relates 
to Dopamine Neuron Loss in Familial PD with PINK1 Mutations. PLoS One 7, e51308. 
128 Parkinson Study Group (1993) Effects of Tocopherol and Deprenyl on the Progression of 
'LVDELOLW\LQ(DUO\3DUNLQVRQ·V'LVHDVHN. Engl. J. Med. 328, 176²183. 
129 Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B & Kanthasamy AG 
(2014) Mitochondria-WDUJHWHGDQWLR[LGDQWVIRUWUHDWPHQWRI3DUNLQVRQ·VGLVHase: 
Preclinical and clinical outcomes. Biochim. Biophys. Acta - Mol. Basis Dis. 1842, 1282²
1294. 
6QRZ%-5ROIH)//RFNKDUW00)UDPSWRQ&02·6XOOLYDQ-')XQJ96PLWK5$-
Murphy MP, Taylor KM & Protect Study Group (2010) A double-blind, placebo-
controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-
PRGLI\LQJWKHUDS\LQ3DUNLQVRQ·VGLVHDVHMov. Disord. 25, 1670²1674. 
131 Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, 
Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao 
S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan 
R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, 
Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, 
Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, 
Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt 
ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, 
Martin WRW, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, 
Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg 
M, Ellias SA, Thomas C-A, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, 
Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, 
Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis 
K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, 
Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer 
KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, 
Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, 
Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala 
N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli 
S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K & Boyar K (2014) A 
Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. 
JAMA Neurol. 71, 543. 
132 Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine 
EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, 
Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey 
M, Lew MF, Liang GSL, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, 
Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer 
C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills A-M & Wills A-M (2015) Effect 
of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. 
JAMA 313, 584. 
133 Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-
James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller 
RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, 
Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, 
Middleton FA, Rochet J-C, Scherzer CR & Global PD Gene Expression (GPEX) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Consortium (2010) PGC-1 , A Potential Therapeutic Target for Early Intervention in 
3DUNLQVRQ·V'LVHDVe. Sci. Transl. Med. 2, 52ra73-52ra73. 
134 NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015) 
3LRJOLWD]RQHLQHDUO\3DUNLQVRQ·VGLVHDVHDSKDVHPXOWLFHQWUHGRXEOH-blind, 
randomised trial. Lancet. Neurol. 14, 795²803. 
135 Kang MY, Oh TJ & Cho YM (2015) Glucagon-Like Peptide-1 Increases Mitochondrial 
Biogenesis and Function in INS-1 Rat Insulinoma Cells. Endocrinol. Metab. 30, 216. 
136 Chen Y, Zhang Y, Li L & Hölscher C (2015) Neuroprotective effects of geniposide in the 
0373PRXVHPRGHORI3DUNLQVRQ·VGLVHDVHEur. J. Pharmacol. 768, 21²27. 
137 Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, 
Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, 
Limousin P, Lees AJ, Greig NH, Tebbs S & Foltynie T (2017) Exenatide once weekly 
YHUVXVSODFHERLQ3DUNLQVRQ·VGLVHDVHDUDQGRPLVHGGRXEOH-blind, placebo-controlled 
trial. Lancet (London, England) 0. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
-
e-
Parkin 
PINK1         mutant
DJ1
Reduced MMP
Abnormal morphology
LRRK2 mutant
Mitophagy
CV
CII CIII
CI
CIV
Reduced ATP production due 
to specific CI or CIV defects
 
 
